Matthias Peipp

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Combination Therapy

Induced Apoptosis

Acute Lymphoblastic Leukemia

Top Venues

Clinical and experimental immunology

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Lennart Lenk, Irène Baccelli, Anna Laqua, Julia Heymann, Claas Reimer, Anna Dietterle, Dorothee Winterberg, Caroline Mary, Frédérique Corallo, Julien Taurelle, Emma Narbeburu, Stéphanie Neyton, Mylène Déramé, Sabrina Pengam, Fotini Vogiatzi, Beat C Bornhauser, Jean-Pierre Bourquin, Simon Raffel, Vladyslava Dovhan, Thomas Schüler, Gabriele Escherich, Monique L Den Boer, Judith M Boer, Wiebke Wessels, Matthias Peipp, Julia Alten, Željko Antić, Anke Katharina Bergmann, Martin Schrappe, Gunnar Cario, Monika Brüggemann, Nicolas Poirier, Denis Martin Schewe
The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis. Blood 143 (26) (2024)
Chilam Chan, J H Marco Jansen, Ilona S T Hendriks, Ida C van der Peet, Meggy E L Verdonschot, Elsemieke M Passchier, Maria Tsioumpekou, Maaike Nederend, Sharon A Klomp, Matthias Peipp, Thomas Valerius, Jeanette H W Leusen, Patricia A Olofsen
Enhancing neutrophil cytotoxicity of a panel of clinical EGFR antibodies by Fc engineering to IgA3.0. Molecular cancer therapeutics (2024)
Lennart Lenk, Irène Baccelli, Anna Laqua, Julia Heymann, Claas Reimer, Anna Dietterle, Dorothee Winterberg, Caroline Mary, Frédérique Corallo, Julien Taurelle, Emma Narbeburu, Stéphanie Neyton, Mylène Déramé, Sabrina Pengam, Fotini Vogiatzi, Beat C Bornhauser, Jean-Pierre Bourquin, Simon Raffel, Vladyslava Dovhan, Thomas Schüler, Gabriele Escherich, Monique L Den Boer, Judith M Boer, Wiebke Wessels, Matthias Peipp, Julia Alten, Željko Antić, Anke Katharina Bergmann, Martin Schrappe, Gunnar Cario, Monika Brüggemann, Nicolas Poirier, Denis Martin Schewe
The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis. Blood 143 (26) (2024)
Lennart Lenk, Irène Baccelli, Anna Laqua, Julia Heymann, Claas Reimer, Anna Dietterle, Dorothee Winterberg, Caroline Mary, Frédérique Corallo, Julien Taurelle, Emma Narbeburu, Stéphanie Neyton, Mylène Déramé, Sabrina Pengam, Fotini Vogiatzi, Beat C Bornhauser, Jean-Pierre Bourquin, Simon Raffel, Vladyslava Dovhan, Thomas Schüler, Gabriele Escherich, Monique L Den Boer, Judith M Boer, Wiebke Wessels, Matthias Peipp, Julia Alten, Željko Antić, Anke Katharina Bergmann, Martin Schrappe, Gunnar Cario, Monika Brüggemann, Nicolas Poirier, Denis Martin Schewe
The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis. Blood 143 (26) (2024)
Lena Hänsch, Matthias Peipp, Maximilian Mastall, Danielle Villars, Renier Myburgh, Manuela Silginer, Tobias Weiss, Dorothee Gramatzki, Flavio Vasella, Markus G Manz, Michael Weller, Patrick Roth
Chimeric antigen receptor (CAR) T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma. Neuro-oncology (2023)
Matthias Peipp, Katja Klausz, Ammelie Svea Boje, Tobias Zeller, Stefan Zielonka, Christian Kellner
Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer. Clinical and experimental immunology 209 (1) (2022)